MedTrace Logo

HT-3951 vs. Placebo in Stroke Rehabilitation

NCT02530307 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2018-02-01

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled parallel group outpatient study that will utilize standard stroke rehabilitation outcome measures, as well as fMRI techniques in a subset of subjects, to evaluate the effect of HT-3951 on motor recovery and behavior in medically stable subjects following ischemic stroke.

Conditions

Interventions

DRUG

HT-3951

DRUG

Placebo

Sponsors & Collaborators

  • Dart NeuroScience, LLC

    lead INDUSTRY

Principal Investigators

  • Philip Perera, MD · Dart NeuroScience, LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02530307 on ClinicalTrials.gov